Meng-xuan Zhu

Zhongshan, 200032, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Identification of clinically relevant subsets CD39+PD-1+CD8+ T cells and CD39+ regulatory T cells in intrahepatic cholangiocarcinoma using single-cell CyTOF.

Identification of clinically relevant subsets CD39+PD-1+CD8+ T cells and CD39+ regulatory T cells in intrahepatic cholangiocarcinoma using single-cell CyTOF.

Journal: Translational oncology
Published: January 21, 2024

Nestin overexpression reduces the sensitivity of gastric cancer cells to trastuzumab.

Nestin overexpression reduces the sensitivity of gastric cancer cells to trastuzumab.

Journal: Journal of gastrointestinal oncology
Published: October 21, 2022

PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma.

PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma.

Journal: Journal of hepatology
Published: September 26, 2021

Circular RNA drives resistance to anti-PD-1 immunotherapy by regulating the miR-30a-5p/SOX4 axis in non-small cell lung cancer.

Circular RNA drives resistance to anti-PD-1 immunotherapy by regulating the miR-30a-5p/SOX4 axis in non-small cell lung cancer.

Journal: Cancer drug resistance (Alhambra, Calif.)
Published: September 19, 2021

Prognostic Signatures Based on Thirteen Immune-Related Genes in Colorectal Cancer.

Prognostic Signatures Based on Thirteen Immune-Related Genes in Colorectal Cancer.

Journal: Frontiers in oncology
Published: August 05, 2020

Circular RNA circ_0020710 drives tumor progression and immune evasion by regulating the miR-370-3p/CXCL12 axis in melanoma.

Circular RNA circ_0020710 drives tumor progression and immune evasion by regulating the miR-370-3p/CXCL12 axis in melanoma.

Journal: Molecular cancer
Published: December 06, 2019

Correction to: Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4.

Correction to: Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4.

Journal: Journal of experimental & clinical cancer research : CR
Published: November 01, 2019

Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4.

Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4.

Journal: Journal of experimental & clinical cancer research : CR
Published: June 06, 2019

Elevated kindlin-2 promotes tumour progression and angiogenesis through the mTOR/VEGFA pathway in melanoma.

Elevated kindlin-2 promotes tumour progression and angiogenesis through the mTOR/VEGFA pathway in melanoma.

Journal: Aging
Published: May 04, 2019

TRIM44 activates the AKT/mTOR signal pathway to induce melanoma progression by stabilizing TLR4.

TRIM44 activates the AKT/mTOR signal pathway to induce melanoma progression by stabilizing TLR4.

Journal: Journal of experimental & clinical cancer research : CR
Published: January 21, 2019

Downregulation of RNF128 activates Wnt/β-catenin signaling to induce cellular EMT and stemness via CD44 and CTTN ubiquitination in melanoma.

Downregulation of RNF128 activates Wnt/β-catenin signaling to induce cellular EMT and stemness via CD44 and CTTN ubiquitination in melanoma.

Journal: Journal of hematology & oncology
Published: January 02, 2019

Bioinformatics-based analysis reveals elevated MFSD12 as a key promoter of cell proliferation and a potential therapeutic target in melanoma.

Bioinformatics-based analysis reveals elevated MFSD12 as a key promoter of cell proliferation and a potential therapeutic target in melanoma.

Journal: Oncogene
Published: June 02, 2018
Showing 1-12 of 12

Last Updated: 09/26/2026